Venetoclax as Salvage Treatment for Relapsed/Refractory B‐ALL Post‐CAR‐T Therapy
Аннотация
ABSTRACT Background Despite high early response rates following chimeric antigen receptor T‐cell therapy (CAR‐T) for relapsed/refractory pediatric B‐cell acute lymphoblastic leukemia (B‐ALL), many patients relapse, and downregulation of the antigen targeted by the CAR‐T has emerged as a major challenge. Furthermore, minimal residual disease (MRD) screening using next‐generation sequencing (NGS) does not inform antigen status. In cases of either antigen downregulation or unknown antigen status, there is a need for antigen‐agnostic salvage agents such as venetoclax. Data regarding venetoclax use in the post‐CAR‐T setting, however, remain limited. Procedure We conducted a retrospective study of patients with B‐ALL who received CAR‐T therapy followed by venetoclax from nine tertiary pediatric oncology centers in the United States. Results Nineteen patients received venetoclax for treatment of relapsed/refractory (R/R) B‐ALL following CAR‐T therapy. The median number of relapses pre‐venetoclax was 2 (range, 1–5). Of 12 patients with known antigen expression status at venetoclax initiation, 11 (92%) had antigen downregulation. Side effects of venetoclax monotherapy were nausea (100%) and rash (25%); in combination chemotherapy, cytopenias (63%) and infections (42%) were also reported. No patient deaths occurred from venetoclax toxicity. After venetoclax, 8 of 19 patients (42%) achieved either morphologic complete remission (CR) or clearance of prior MRD. Of 11 patients with baseline MRD‐only disease, 4 (36%) achieved MRD negativity. Of 8 patients with baseline morphologic disease, 2 (25%) achieved morphologic CR. Patients with antigen downregulation had a 29% morphologic CR rate. Conclusions Our experience suggests tolerability and promise of venetoclax in pediatric R/R B‐ALL, including patients with antigen downregulation.